Capricor Therapeutics (CAPR)
(Real Time Quote from BATS)
$5.73 USD
-0.37 (-6.07%)
Updated May 29, 2024 02:02 PM ET
4-Sell of 5 4
F Value B Growth B Momentum D VGM
Capricor Therapeutics (CAPR) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$19.80 | $40.00 | $8.00 | 224.59% |
Price Target
Based on short-term price targets offered by five analysts, the average price target for Capricor Therapeutics comes to $19.80. The forecasts range from a low of $8.00 to a high of $40.00. The average price target represents an increase of 224.59% from the last closing price of $6.10.
Analyst Price Targets (5 )
Broker Rating
Capricor Therapeutics currently has an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by five brokerage firms. The current ABR compares to an ABR of 1.00 a month ago based on four recommendations.
Of the five recommendations deriving the current ABR, five are Strong Buy, representing 100% of all recommendations. A month ago, Strong Buy represented 100%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 5 | 5 | 4 | 4 | 4 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
5/14/2024 | LadenburgThalmann | Aydin Huseynov | Strong Buy | Strong Buy |
5/14/2024 | Cantor Fitzgerald & Co | Kristen Kluska | Strong Buy | Strong Buy |
3/1/2024 | H.C. Wainwright & Co. | Joseph Pantginis | Strong Buy | Strong Buy |
10/20/2023 | Maxim Group | Jason Mccarthy | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.00 |
ABR (Last week) | 1.00 |
# of Recs in ABR | 5 |
Average Target Price | $19.80 |
LT Growth Rate | NA |
Industry | Medical - Products |
Industry Rank by ABR | 94 of 252 |
Current Quarter EPS Est: | -0.32 |